BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Skinvisible, Inc. (SKVI) Granted U.S. Patent for Stabilizing Retinoids


11/28/2012 9:14:35 AM

LAS VEGAS, NV--(Marketwire - November 27, 2012) - Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI) (OTCBB: SKVI) today announced that it has been granted US Patent Number 8,299,122 for combining retinoic acid with its patented polymer delivery system, Invisicare®. The patent issued by the United States Patent and Trademark Office (USPTO) titled "Methods for Stabilizing Retinoids, Retinoid Containing Composition, and Methods of Using a Retinoid Containing Composition," will provide protection until April 14, 2029.

Retinoic acid (tretinoin) is a retinoid which is commonly used in prescription drugs to treat acne, psoriasis and skin cancer. Retinoids however degrade in the presence of light and oxygen. Skinvisible's invention stabilizes retinoic acid, enhancing the life and efficacy of compositions containing retinoic acid. Additionally this patent relates to a method for stabilizing a retinoid, and to a retinoid containing composition.

The granting of this retinoid patent further substantiates Skinvisible's findings that Invisicare provides major benefits to the topical formulations it develops. In addition to the stabilization of retinoic acid, Invisicare also controls the release of the active, providing a gradual release over time that can decrease irritation caused by the active ingredient. Since acne continues to be the largest prescription market in dermatology with estimated sales of US $2.3 billion worldwide, Skinvisible has developed three additional acne formulations: adapalene, clindamycin and salicylic acid, all of which are available for exclusive licensing.

"We are pleased to receive this patent which increases the depth of intellectual property protection, especially as it pertains to our high-value acne formulations," said Terry Howlett, President and CEO. "This patent provides potential licensees with a further layer of exclusivity and will assist Skinvisible as it actively seeks partnering, licensing and co-development arrangements globally to maximize the potential of this recently issued patent."

Skinvisible continues to proactively build and strengthen its global patent portfolio for Invisicare as well as its forty plus prescription, over-the-counter and cosmeceutical formulations it has developed. Skinvisible has received patent approval for Invisicare in the following major countries: U.S.(2), Canada, Europe(4), Australia, India, Japan, China, Hong Kong and S. Korea and three product specific patents covering its dermal barrier products, sunscreen formulations and now retinoids. The Company expects to be granted additional patents shortly including further expansion of its Invisicare technology patents as well as valuable targets for dermatology products.

About Skinvisible Pharmaceuticals, Inc
Skinvisible Pharmaceuticals is a research-and-development company that licenses its proprietary formulations made with Invisicare, its patented polymer delivery system that offers life-cycle management and unique enhancements for topically delivered products. Invisicare holds active ingredients on the skin for extended periods of time resisting both wash off and perspiration along with controlling the release of actives and reducing irritation. Skinvisible receives a combination of license fees, and ongoing royalties for its licensed product formulations. Skinvisible's value also lies in its ability to continually generate new IP on topical products formulated with Invisicare. www.skinvisible.com and www.invisicare.com.

Forward-Looking Statements: This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending September 30, 2012).


Corporate Contact:
Doreen McMorran
Skinvisible Pharmaceuticals, Inc.
Phone: 702-433-7154
Email: info@skinvisible.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES